Chelsea and Westminster Hospital NHS Foundation Trust Medicines Committee
Summary of Main Points from the Meeting held on the 13th of December 2010

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes were approved and would be circulated.

3. Matters Arising

- The **Medicines Policy Audit 2010** and the **Medicines Management Annual Report 2009-10** were updated following the comments from the Trust Quality Committee and would be published on the Trust Intranet.
- **Double checking by Anaesthetists** – The letter to the Safer Anaesthesia Liaison Group (SALG) would be sent to the Chair of SALG, Prof. Mahajan, to enquire as to when the guidance on anaesthetist double checking would be expected.
- **Updated Medicines Policy Sections - Section 4 - Safe Storage of Medicines & Section 8 – Administration** have been published on the Trust Intranet.
- **Strategy for reducing unnecessary prescribing of PPIs**
  - *Ensure the need for PPI is reviewed at Preoperative Assessment Clinic*
    The Lead Directorate Pharmacist for Surgery would liaise with the Divisional Medical Director for medicine and Surgery to ensure that PPIs are reviewed at Preoperative Assessment Clinic.
  - *Develop a prompt on the electronic prescribing system to prompt review of PPI indication and duration at point of prescribing.*
    The EPR proposal to implement a prompt a prompt at the visual table selection point of the prescribing process would undergo further review before final sign-off.
  - *Develop a checklist for review of PPI indication and duration at admission together with Medicine Directorate.*
    The checklist had been approved by the gastroenterologists and would go to the Medicine Directorate meeting in December for approval. If approved by Medicine, then it was agreed it could receive Chairman's action from the Medicines Committee for immediate implementation.
- **NMP Audit Report March 2010** - The audit report had been updated and would be disseminated.

4. New Medicines Applications

- **Denosumab injection**

Denosumab was requested for treatment of osteoporosis in postmenopausal women at increased risk of fracture as a 3rd line agent when other therapies have failed in line with NICE Guidance.
Decision: Approved for restricted use according to NICE Guidance.
Tariff status: It is currently in-tariff; however it is expected to be listed as tariff excluded from 01/04/2011.

Ex panel requests –in-tariff medicines

- **Chloroquine 250mg tablets**

Decision: Approved. In-tariff medicine. Considered first line for the treatment of malaria.

- **Prochlorperazine 3mg buccal tablets**

Buccastem (prochlorperazine) buccal 3mg tablets were approved for treatment of hyperemesis gravidarum now that Stemetil® (prochlorperazine) suppositories have been discontinued.

- **Balneum**

Roved for the symptomatic relief of dry and very dry skin conditions

- **Epiduo gel**

Epiduo gel was approved for cutaneous treatment of acne vulgaris when comedones, papules and pustules are present and as an alternative to prescribing Adapalene 0.1%/ Benzoyl peroxide 2.5%, separately.

5. Reviewed Medicines Policy Sections Approved

- **Section 2 - Prescribing**

This section was updated to incorporate recommendations from an incident review relating to the loss of an FP10HP pad at an off-site clinic. The update includes the requirement for professionally registered staff to collect the pads from Pharmacy, reinforcing safe storage and requiring all prescriptions issued to be logged on a log sheet.

- **Section 22 - Non-medical Prescribing**

This section had previously been updated to include all of the detail relating to the safe storage and issue of FP10HP prescription pads. Subsequent to the update of Section 2 above, this detail was removed and replaced with a reference to Section 2- Prescribing (2.6.3).

6. NPSA Alerts –Completed Action Plans

The following completed action plans were noted:

- Action plan for NPSA Alert on Vaccines & Cold storage
- Action Plan for NPSA alert 'reducing dosing errors with opioid medicines' action plan

7. November 2010 Trusts Progress – Specific Medicines Related CQUIN targets

In November 2010, the Trust achieved the stretch target of 95% for hospital initiated PPIs and the standard target of 85% for antibiotics. The antibiotic performance dropped due to 2 HIV prescriptions for ongoing prophylaxis that did not have the indication specified. As an ongoing reminder, ALL hospital initiated PPIs and ALL antibiotics MUST contain an indication and duration for the GP either written in the WP box or in the DSUM text, even in the case of long term antibiotic prophylaxis.

8. Shared Care Guidance

The flowing Shared Care Guidance Documents were approved by the committee and would be published on the Trust Intranet:

- Growth hormone (for children)
- Attention Deficit - Hyperkinetic Disorder (ADHD) in children and young people

9. NICE Guidance

The committee noted the following NICE Guidance – neither were applicable to C& W

- TA208 – Gastric cancer (HER2-postive metastatic) – trastuzumab
- TA209 – Gastrointestinal stromal tumours (unresectable/metastatic)- imatinib

10. IVIG Update

- The updated IVIG process was approved.
- IVIG report for November.

There were 8 IVIG issues in November 2010, with 2 new requests. One was for adult HIV associated thrombocytopaenia (blue – selected) and one for a Kawasaki's patient (red - selected). The committee approved the IVIG issues.

11. Items for Noting

The following items were noted by the Committee:

- Medicines Management Programme of Development review
- Updated Medicines Management Training Programme 2010 *

*Noted pending a review of the requirement for consultants and registrars to have 2 yearly mandatory Medicines Management updates.

- Usage review: Sugammadex®,

Sugammadex was approved in April 2010 for the immediate reversal of rocuronium / vecuronim-induced block in the following situations only:

- ❖ Cannot ventilate / cannot intubate scenario
- ❖ Reversal from moderate or deep block where prolonged anaesthesia would be detrimental to patient care
- ❖ Residual neuromuscular blockade in recovery reversed with standard doses of neostigmine and glycopyrrolate

There had been no usage since August 2010 when it was introduced. However, the stock was short-dated and expired in October 2010. Pharmacy will follow up as they should not have received short dated stock.

- CD Quarterly report Q2 and CD Occurrence Report.

There were 4 occurrence reported in Q2. The loss from Pharmacy of 10mg injection, 50 x midazolam 10mg/2ml injection and a part used CD requisition book was of most concern and was subject to an orange incident panel review. The reports were noted by the committee.

12. Papers to go to the Trust Executive Clinical Governance Committee

The following papers should be sent to the Trust Executive Team – Clinical Governance Meeting:

- Medicines Committee Summary Notes November 2010
- Updated Medicines Management Training Programme

Date of the next meeting

Monday 14th of February March 2010, 08.00 to 09.00, St Stephen's Kitchen Meeting Room
Closing date for papers: Friday 21st of January 2011